From Patients to Partners: Early Insights from a Patient-Led Care Model Following Psychedelic Treatment

As psychedelic-assisted therapies progress through late-stage clinical development, increasing attention is being paid to models of care that support patients beyond the acute treatment period. While clinical trials demonstrate rapid and substantial symptom improvement, less is known about how structured post-treatment support may contribute to sustained recovery, self-efficacy, and functional outcomes. 

PsyPAN (Psychedelic Participant Advocacy Network), with grant support from Atai and Beckley Psytech (now AtaiBeckley), implemented a 12-month peer support pilot involving 20 former clinical trial participants. The programme was designed in response to participant-identified needs for community connection, shared experience, and practical tools to integrate therapeutic insights into daily life. An independent academic evaluation is being conducted by Exeter University to assess qualitative outcomes. 

This presentation will share early learnings from the pilot, including participant-reported impacts on emotional regulation, self-management, social functioning, and ongoing well-being. Observations suggest a progression from reliance on structured support toward increased autonomy and resilience, with participants engaging in diverse supportive practices such as healthy lifestyle changes, embodiment approaches, and community-based connection. 

The findings offer preliminary evidence that patient-led peer support may represent a scalable, low-cost adjunct to psychedelic treatment pathways. Implications for healthcare systems include potential benefits for long-term outcomes, reduced reliance on clinical resources, and enhanced patient empowerment. 

These early insights highlight the importance of considering sustainable post-treatment care models alongside drug development, and support further research into peer-supported approaches as part of integrated psychedelic-assisted therapy ecosystems.